GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Fosfomycin disodium IV (CONTEPO)

Local official-label summaryBase record retrieved 2026-09-07See the evidence for this drug2 sources available - open source summaries, references and comparisons

CONTEPO

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (2)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

2 additional source qualifications - review before use
IV loading/maintenance table does not fill every renal setting

CONTEPO supplies integer CrCl bands from 11 through 50 and post-HD timing, but the table does not provide a <=10 or CRRT maintenance regimen.

Before applying: Do not interpolate uncovered thresholds or derive a regimen from dialysis-removal percentages. Keep the sodium load and renal reassessment visible.

CONTEPO: a returned page can still omit the renal dosing table

The new RX card contains selected safety and pharmacokinetic information only. Its retrieved rendering lacked the dosing table; the prior official card is retained separately.

Before applying: Do not use the limited RX card as a substitute dose table or confuse intravenous CONTEPO with oral fosfomycin.

Also check: IV loading/maintenance table does not fill every renal setting; CONTEPO: a returned page can still omit the renal dosing table

Official source

Fosfomycin disodium IV (CONTEPO)

Product / population
CONTEPO IV for adults >=18 with susceptible-organism cUTI including acute pyelonephritis; not oral fosfomycin.
Renal measure
Cockcroft-Gault CrCl mL/min; integer renal bands reproduced without interpolation.

Renal dosing, restrictions and evidence limits

CrCl >50: 6 g IV every 8 hours. Renal table: give a 6 g loading dose, then 4 g every 8 hours at 41-50; 3 g every 8 hours at 31-40; 5 g every 24 hours at 21-30; 3 g every 24 hours at 11-20. Infuse each dose over one hour; treatment is up to 14 days according to clinical status. Reassess CrCl during treatment.

Give after hemodialysis on dialysis days. This table supplies no maintenance regimen at CrCl <=10 or for CRRT; do not invent one from dialysis removal percentages. Each vial contains 1980 mg sodium: monitor electrolytes, fluid status and edema.

Source revision: Prescribing information 10/2025; SPL effective 2025-11-04 | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=855574f2-39f8-43bc-a3d2-79dbb578cb94&type=display

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 2 source difference / applicability notes

Official product label

Fosfomycin disodium IV (CONTEPO)

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

CONTEPO IV for adults >=18 with susceptible-organism cUTI including acute pyelonephritis; not oral fosfomycin.

Renal method: Cockcroft-Gault CrCl mL/min; integer renal bands reproduced without interpolation.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - CONTEPO

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

CONTEPO intravenous fosfomycin; not oral fosfomycin tromethamine. The returned RX rendering omits its dosing table.

Renal method: CrCl, mL/min; selected pharmacokinetics and safety sections only.
Retrieved: 2026-09-08

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 2 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

evidence gap

IV loading/maintenance table does not fill every renal setting

CONTEPO supplies integer CrCl bands from 11 through 50 and post-HD timing, but the table does not provide a <=10 or CRRT maintenance regimen.

How to use this: Do not interpolate uncovered thresholds or derive a regimen from dialysis-removal percentages. Keep the sodium load and renal reassessment visible.

Fosfomycin disodium IV (CONTEPO)Fosfomycin - oral

Source-specific interpretation; independent clinician adjudication pending.

source quality

CONTEPO: a returned page can still omit the renal dosing table

The new RX card contains selected safety and pharmacokinetic information only. Its retrieved rendering lacked the dosing table; the prior official card is retained separately.

How to use this: Do not use the limited RX card as a substitute dose table or confuse intravenous CONTEPO with oral fosfomycin.

GlobalRPh RX List - CONTEPOFosfomycin - oral

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeFosfomycin disodium IV (CONTEPO)GlobalRPh RX List - CONTEPO
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=855574f2-39f8-43bc-a3d2-79dbb578cb94&type=display

Exact product and population

CONTEPO IV for adults >=18 with susceptible-organism cUTI including acute pyelonephritis; not oral fosfomycin.

RDM41-SCOPE-fosfomycin-contepo-iv · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Fosfomycin disodium IV (CONTEPO)

Open original reference

Open / share this exact local source

DailyMed / Meitheal Pharmaceuticals Inc. · CONTEPO IV for adults >=18 with susceptible-organism cUTI including acute pyelonephritis; not oral fosfomycin.

Renal method: Cockcroft-Gault CrCl mL/min; integer renal bands reproduced without interpolation.
Source date: Prescribing information 10/2025; SPL effective 2025-11-04
Retrieved: 2026-09-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

CrCl >50: 6 g IV every 8 hours. Renal table: give a 6 g loading dose, then 4 g every 8 hours at 41-50; 3 g every 8 hours at 31-40; 5 g every 24 hours at 21-30; 3 g every 24 hours at 11-20. Infuse each dose over one hour; treatment is up to 14 days according to clinical status. Reassess CrCl during treatment.

Give after hemodialysis on dialysis days. This table supplies no maintenance regimen at CrCl <=10 or for CRRT; do not invent one from dialysis removal percentages. Each vial contains 1980 mg sodium: monitor electrolytes, fluid status and edema.

RDM41-official-fosfomycin-contepo-iv-cabe7628e7-C1 · Source locator: Sections 1.1, 2.1-2.2, 5.1; SPL metadata

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=855574f2-39f8-43bc-a3d2-79dbb578cb94&type=display
Retrieved
2026-09-07
Exact label title
Fosfomycin disodium IV (CONTEPO)
DailyMed Set ID
855574f2-39f8-43bc-a3d2-79dbb578cb94
Labeler
Meitheal Pharmaceuticals Inc.
Label revision
Prescribing information 10/2025; SPL effective 2025-11-04
SPL version
10
Renal-function method
Cockcroft-Gault CrCl mL/min; integer renal bands reproduced without interpolation.
Source date/version
Prescribing information 10/2025; SPL effective 2025-11-04
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
a22621841a570ca754af79705481a693e169934f31f604da55f2f0a10872341a
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - CONTEPO

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · CONTEPO intravenous fosfomycin; not oral fosfomycin tromethamine. The returned RX rendering omits its dosing table.

Renal method: CrCl, mL/min; selected pharmacokinetics and safety sections only.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-08

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The RX pharmacokinetic section calls for adjustment at CrCl <=50 and reports removal by hemodialysis. The dosing table was not present in the retrieved rendering, so this card does not specify a regimen. Sodium-related fluid overload and electrolyte abnormalities remain relevant safety concerns. The separately retained official source, not this incomplete RX rendering, contains renal table instructions.

RDM44-rxlist-fosfomycin-contepo-iv-cd2b7b8d43-C1 · Source locator: Warnings: fluid overload/electrolytes, lines 131-134; renal pharmacokinetics, lines 208-209; dosing-table retrieval limitation.

Source-specific limits

Limited-section import only. Omitted dosing table remains an open source-quality limitation.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/contepo-drug/
Retrieved
2026-09-08
Renal-function method
CrCl, mL/min; selected pharmacokinetics and safety sections only.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
84cd11013eb639a0c7339a27302d2c780f7847136b4ab4488bc7423567d54823

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=855574f2-39f8-43bc-a3d2-79dbb578cb94&type=display
Source retrieval
2026-09-07. This is not the source publication or label revision date.
Original source type
source summary
Local text SHA-256
9f6964236e7c3661935142fc4883ad3b674c83d7d97ed790f32fbfea0a0d43e0
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report